Search
Sevuparin
go.drugbank.com/drugs/DB15007InvestigationalSevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).
Ofranergene obadenovec
go.drugbank.com/drugs/DB15175InvestigationalOfranergene obadenovec is under investigation in clinical trial NCT01229865 (Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid Cancer).
MLN576
go.drugbank.com/drugs/DB06517ExperimentalXR11576 (MLN576) is a novel monophenazine with a mechanism of action that includes interaction with both topoisomerase (Topo) I and II.[A234609]
Novaferon
go.drugbank.com/drugs/DB16483InvestigationalCategories: Amino Acids, Peptides, and Proteins, Intercellular Signaling Peptides and ProteinsKD3010
go.drugbank.com/drugs/DB05188ExperimentalKD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine
go.drugbank.com/drugs/DB13948ExperimentalIt has been tested with regard to the head-twitch-response (HTR) model of 5-HT2A activity and effects on locomotion [L1148]. It was discovered in 2014 at the University of Copenhagen.
Ladostigil
go.drugbank.com/drugs/DB16213InvestigationalLadostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Nanrilkefusp alfa
go.drugbank.com/drugs/DB17480InvestigationalNanrilkefusp alfa is a human fusion protein consisting of the cytokine interleukin (IL)-15 and the high-affinity binding sushi+ domain of IL-15 receptor alpha (IL-15Ra).
BEA-17
go.drugbank.com/drugs/DB18574ExperimentalBEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST.[L48330] It is under investigation for the treatment of glioblastoma.
Navtemadlin
go.drugbank.com/drugs/DB15299InvestigationalNavtemadlin (AMG-232) is under investigation in clinical trial NCT03041688 (MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia